Vyant Bio - Stock Price History | VYNT

Historical daily share price chart and data for Vyant Bio since 2021 adjusted for splits. The latest closing stock price for Vyant Bio as of September 27, 2021 is 2.34.
  • The all-time high Vyant Bio stock closing price was 630.63 on September 27, 2013.
  • The Vyant Bio 52-week high stock price is 17.50, which is 647.9% above the current share price.
  • The Vyant Bio 52-week low stock price is 2.11, which is 9.8% below the current share price.
  • The average Vyant Bio stock price for the last 52 weeks is 3.63.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Vyant Bio Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 3.4711 5.5300 6.2500 2.0900 2.7700 -53.52%
2019 5.7596 7.5075 13.2132 2.0800 5.9600 -17.99%
2018 33.0887 58.5586 63.0631 6.0811 7.2673 -86.92%
2017 92.3256 42.0420 151.6517 42.0420 55.5556 37.04%
2016 62.9523 97.2973 99.3994 33.0330 40.5405 -59.09%
2015 249.7764 233.6336 373.5736 84.9850 99.0991 -50.60%
2014 343.0863 418.0180 600.6006 149.8498 200.6006 -51.52%
2013 370.2825 337.8378 630.6306 273.2733 413.8138 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.068B $0.006B
VYANT BIO INC. operates through wholly-owned subsidiaries, StemoniX and vivoPharm. StemoniX is empowering the discovery of new medicines through the convergence of novel human biology and software technologies. vivoPharm offers proprietary preclinical test systems supporting clinical diagnostic offerings at early stages valued by the pharmaceutical industry, biotechnology companies, and academic research centers. VYANT BIO INC., formerly known as Cancer Genetics Inc., is based in CHERRY HILL, N.J.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29